Literature DB >> 7259925

Cimetidine-a clinical and pharmacokinetic study.

J Webster, H E Barber, G M Hawksworth, T A Jeffers, J Petersen, J C Petrie, P W Brunt, N A Mowat, R Griffiths.   

Abstract

1 The effect of six months therapy with cimetidine (800 mg or 1600 mg/day) and subsequent withdrawal was studied in 19 patients with duodenal ulceration. 2 The overall rates of healing were 63% and 79% of patients after 3 and after 6 months of treatment respectively. The longer course (6 months) or the higher dose (1600 mg) did not result in significantly increased rates of ulcer healing. 3 Abrupt withdrawal of cimetidine resulted in the recurrence of severe symptoms in 15 patients (79%). 4 Pharmacokinetic studies showed the mean elimination half-life of cimetidine to be 100 +/- 25 min, the total body cimetidine clearance 652 +/- 223 ml/min, the mean volume of distribution at steady state 65 +/- 181 and the overall bioavailability 78%. 5 Long term cimetidine treatment does not result in drug accumulation or changes in its pharmacokinetic profile. 6 Inter-individual differences in clinical and endoscopic response to cimetidine cannot be explained by pharmacokinetic differences.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7259925      PMCID: PMC1401673          DOI: 10.1111/j.1365-2125.1981.tb01129.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-receptor antagonist, in blood and urine.

Authors:  W C Randolph; V L Osborne; S S Walkenstein; A P Intoccia
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

2.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  Curve fitting by spline and Akima methods: possibility of interpolation error and its suppression.

Authors:  J Fried; S Zietz
Journal:  Phys Med Biol       Date:  1973-07       Impact factor: 3.609

5.  Bioavailability and pharmacokinetics of cimetidine.

Authors:  A Grahnén; C von Bahr; B Lindström; A Rosén
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

6.  The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.

Authors:  G Bodemar; B Norlander; L Fransson; A Walan
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

7.  Bioavailability of cimetidine in man.

Authors:  S S Walkenstein; J W Dubb; W C Randolph; W J Westlake; R M Stote; A P Intoccia
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

8.  Pharmacokinetics and bioavailability of cimetidine in humans.

Authors:  P V Pedersen; R Miller
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

9.  Cimetidine in the treatment of active duodenal and prepyloric ulcers.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

10.  Prevention by bedtime cimetidine of duodenal-ulcer relapse.

Authors:  W S Blackwood; D P Maudgal; T C Northfield
Journal:  Lancet       Date:  1978-03-25       Impact factor: 79.321

  10 in total
  10 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Pharmacokinetics of cimetidine after subchronic administration.

Authors:  T W Chin; M Spino; S M MacLeod; W A Mahon; S J Soldin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

5.  Cimetidine bioavailability and variable renal clearance.

Authors:  A Grahnén
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Refractory duodenal ulcer.

Authors:  K D Bardhan
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

Review 7.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

9.  Pharmacokinetics of cimetidine in advanced cirrhosis.

Authors:  A Grahnén; S Jameson; L Lööf; J Tyllström; B Lindström
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.